Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?

Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?

Watkins Richard R; Deresinski Stan

Expert review of anti-infective therapy

2015

2015-04

Carbapenem-resistant Klebsiella pneumoniae causes serious nosocomial infections and therapeutic options are limited. There is increasing evidence suggesting that combination antibiotic therapy is more effective than monotherapy and leads to better outcomes. However, questions remain about which regimen is optimal and how to balance the potential benefits of combination therapy versus the risks and possible complications (e.g., toxicity, increased costs, Clostridium difficile infection). Well-designed randomized clinical trials are needed to clarify these issues.

Humans; Randomized Controlled Trials as Topic; Anti-Bacterial Agents/*therapeutic use; beta-Lactam Resistance/genetics; carbapenem-resistant Klebsiella pneumoniae; Carbapenems/*therapeutic use; combination antibiotic therapy; Klebsiella Infections/*drug therapy/microbiology; Klebsiella pneumoniae/*drug effects/genetics/pathogenicity; Drug Therapy; Combination/*statistics & numerical data

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

405–407

4

13